Institute of Genetic Medicine, University of Newcastle, Newcastle, United Kingdom.
Institute of Biomedical and Clinical Sciences, Medical School, College of Medicine and Health, University of Exeter, Exeter, United Kingdom.
Elife. 2019 Sep 3;8:e47678. doi: 10.7554/eLife.47678.
Prostate is the most frequent cancer in men. Prostate cancer progression is driven by androgen steroid hormones, and delayed by androgen deprivation therapy (ADT). Androgens control transcription by stimulating androgen receptor (AR) activity, yet also control pre-mRNA splicing through less clear mechanisms. Here we find androgens regulate splicing through AR-mediated transcriptional control of the epithelial-specific splicing regulator . Both and its close paralog are highly expressed in primary prostate cancer. Androgen stimulation induces splicing switches in many endogenous ESRP2-controlled mRNA isoforms, including splicing switches correlating with disease progression. expression in clinical prostate cancer is repressed by ADT, which may thus inadvertently dampen epithelial splice programmes. Supporting this, treatment with the AR antagonist bicalutamide (Casodex) induced mesenchymal splicing patterns of genes including and . Our data reveals a new mechanism of splicing control in prostate cancer with important implications for disease progression.
前列腺是男性最常见的癌症。前列腺癌的进展是由雄激素类固醇激素驱动的,并通过雄激素剥夺疗法(ADT)延迟。雄激素通过刺激雄激素受体(AR)的活性来控制转录,但也通过不太明确的机制控制前体 mRNA 的剪接。在这里,我们发现雄激素通过 AR 介导的上皮特异性剪接调节剂 的转录控制来调节剪接。 和它的密切同源物 都在原发性前列腺癌中高度表达。雄激素刺激诱导许多内源性 ESRP2 控制的 mRNA 异构体的剪接转换,包括与疾病进展相关的剪接转换。 在临床前列腺癌中的表达受 ADT 抑制,这可能会无意中抑制上皮剪接程序。支持这一点,用 AR 拮抗剂比卡鲁胺(Casodex)治疗诱导了包括 和 在内的基因的间充质剪接模式。我们的数据揭示了前列腺癌中剪接控制的新机制,对疾病进展具有重要意义。